Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with theratope STn-KLH cancer vaccine

Journal of Immunotherapy

Volumn 22, Issue 1, 1999, Pages 54-66

  Sandmaier, Brenda M ^a,b   Oparin, Dimitry V ^a   Holmberg, Leona A ^a,b   Reddish, Mark A ^c   MacLean, Grant D ^c   Longenecker, B Michael ^c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Biomira Inc   (Canada)

Author keywords

Carbohydrate antigen; Cellular immune response; Immunotherapy; Sialyl Tn; Stem cell rescue

Indexed keywords

CANCER VACCINE; CARBOHYDRATE ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; SIALIC ACID DERIVATIVE; THERATOPE STN KLH CANCER VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BONE MARROW RESCUE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOCYANIN; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MUCINS; OVARIAN NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032943932     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199901000-00008     Document Type: Article

References (44)

1. Borges E, Wiesmuller K-H, Jung G. Walden P. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J Immunol Methods 1994;173:253-63.
2. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
3. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992;84:1084-91.
4. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-90.
5. Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
6. MacLean GD, Reddish MA, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993;36:215-22.
7. Longenecker BM, Reddish M, Koganty R, MacLean GD. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus DETOX adjuvant. Ann NY Acad Sci 1993;690:276-91.
8. MacLean GD, Reddish MA, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 1996;19: 59-68.
9. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low dose intravenous cyclophosphamide. J Immunother 1996;19:309-16.
10. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118-24.
11. Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconjugate J 1997;14:549-60.
12. Yamasha Y, Chung YS, Horie R, Kaonagi R, Sowa M. Alterations in gastric mucin with malignant transformation: novel pathway for mucin synthesis. J Natl Cancer Inst 1995;87:441-6.
13. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S-I, Kim YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66:1960-6.
14. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992;10:95-101.
15. Werther JL, Rivera-MacMurray S, Tatematsu M, Ito N, Bruckner H, Itzkowitz SH. Sialosyl-Tn: a novel mucin antigen associated with poor prognosis in gastric cancer patients. Proc Am Assoc Cancer Res 1991;32:241.
16. Longenecker BM, Reddish M, Miles D, MacLean GD. Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res 1993;2:151-62.
17. Fung PS, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-Ha). Cancer Res 1991;51: 1170-6.
18. + lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996;42:303-9.
19. Agrawal B, Krantz, MJ, Reddish MA, Longenecker BM. Cancer associated MUC-1 mucin inhibits human T-cell proliferation which is reversible by IL-2. Nature Med 1998;4:43-9.
20. Longenecker BM, Reddish M, Miles D, MacLean GD. Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res 1993;2:151-62.
21. + activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 1995;61:470-4.
22. Miles DW, Towlson KE, Graham R, et al. A randomised phase II study of sialyl-Tn and DETOX-B™ adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996;74:1292-6.
23. Henningsson C, Selvaraj S, MacLean GD, Suresh MR, Noujaim AA, Longenecker BM. T-cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T-cell immunity in vivo. Cancer Immunol Immunother 1987;25:231-41.
24. Singhal A. Fohn M, Hakomori S-I. Induction of α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 1991;51:1406-11.
25. Harding CV, Kihlberg J, Elofsson M, Magnusson G, Unanue ER. Glycopeptides bind MHC molecules and elicit specific T cell responses. J Immunol 1993;151:2419-25.
26. Haurum JS, Arsequell G, Lellouch AC, et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994; 180:739-44.
27. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994;180:745-9.
28. Deck B, Elofsson M, Kihlberg J, Unanue ER. Specificity of glycopeptide-specific T cells. J Immunol 1995;155:1074-8.
29. Jensen T, Galli-Stampino L, Mouritsen S, et al. T cell recognition of Tn-glycosylated peptide antigens. Eur J Immunol 1996;26: 1342-9.
30. Galli-Stampino L, Meinjohanns E, Frische K, et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 1997;57:3214-22.
31. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984;224:1198-206.
32. Storek J, Witherspoon RP. Immunological reconstitution after hemopoietic stem cell transplantation. In: Atkinson K, ed. Clinical bone marrow and blood stem cell transplantation: a reference textbook, 2nd ed. Cambridge University Press (in press).
33. Reddish M, Black N, Almeida A, Suresh MR, Longenecker BM. Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for the human MUC1 gene. J Tumor Marker Oncol 1992;7:19-27.
34. Chan DW, Beveridge RA, Muss H, et al. Use of TRUQUANT BR RIA for the early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997;15:2322-8.
35. Capstick V, MacLean GD, Suresh MR, et al. Clinical evaluation of a new two-site assay for CA125 antigen. Int J Biol Markers 1991; 6:129-35.
36. Agrawal B, Reddish MA, Longenecker BM. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 1996;157:2089-95.
37. Abacus Concepts. Survival tools for STATVIEW. Berkeley, CA: Abacus Concepts, 1994.
38. Barra A, Cordonnier C, Preziosi MP, et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992;166:1021-8.
39. Witherspoon RP, Matthews D, Storb R, et al. Recovery of in vivo cellular immunity after human marrow grafting. Transplantation 1984;37:145-50.
40. Atkinson K. Reconstitution of the haematopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990;5:209-26.
41. Zhang S, Walberg LA, Ogata S, et al. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 1995;55:3364-8.
42. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984;50:765-9.
43. MacLean GD, Bowen-Yacyshyn MB, Samuel J, et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 1992;11:292-305.
44. Fung, PYS, Madej M, Koganty R, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990;50: 4308-15.